Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRI) Equity Average (2020 - 2025)

Biofrontera has reported Equity Average over the past 6 years, most recently at $3.9 million for Q4 2025.

  • For Q4 2025, Equity Average fell 20.72% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, down 20.72%, while the annual FY2025 figure was $7.5 million, 61.64% up from the prior year.
  • Equity Average for Q4 2025 was $3.9 million at Biofrontera, up from -$3.6 million in the prior quarter.
  • Over five years, Equity Average peaked at $23.2 million in Q4 2022 and troughed at -$9.4 million in Q3 2021.
  • A 5-year average of $6.1 million and a median of $4.0 million in 2021 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: skyrocketed 3641.79% in 2022 and later tumbled 175.85% in 2025.
  • Year by year, Equity Average stood at -$3.0 million in 2021, then surged by 869.17% to $23.2 million in 2022, then tumbled by 87.45% to $2.9 million in 2023, then skyrocketed by 70.86% to $5.0 million in 2024, then dropped by 20.72% to $3.9 million in 2025.
  • Business Quant data shows Equity Average for BFRI at $3.9 million in Q4 2025, -$3.6 million in Q3 2025, and -$2.1 million in Q2 2025.